摘要
目的观察阿帕替尼及卡培他滨治疗三线及以上药物治疗失败的晚期胃癌患者的疗效及副反应，比较两者优劣性。方法2015年1月至2016年8月经病理确诊、既往未曾应用靶向药物及卡培他滨化疗、曾经过三线及患者的以上药物治疗失败的晚期胃癌患者68例，分别给予阿帕替尼片及卡培他滨片，直至疾病进展或连续评价6个周期，观察临床疗效及不良反应发生情况。结果阿帕替尼组疾病控制率（DCR）优于卡培他滨，差异有统计学意义（P〈0．05）。阿帕替尼组和卡培他滨组患者的中位无进展生存期（PFS）分别为3．6个月和3．5个月，差异无统计学意义（P〉0.05）。卡培他滨组白细胞减少及血小板减少比阿帕替尼组高；阿帕替尼组高血压、蛋白尿比卡培他滨组偏高，差异有统计学意义。结论阿帕替尼与卡培他滨在三线及以上药物治疗失败的晚期胃癌中，近期疗效阿帕替尼略优于卡培他滨，远期中位生存时间无明显差异，两者毒副反应各不相同，阿帕替尼主要为高血压、蛋白尿，而卡培他滨主要为骨髓抑制，但总体而言，毒副作用低，耐受性可，值得临床推广使用。
Objective To evaluate the efficacy and safety of apatinib compared with capecitabine in advanced gastric cancer patients after failure of third-line or beyond treatment. Methods From January 2015 to August 2016, 68 patients with pathologically confirmed advanced gastric cancer who failed of third line or beyond treatment were enrolled in the study. 35 patients were given apatinib for 500 mg/noce qd Po and the other 33 patients were given capecitabine tablets for 1250 mg/m2/time qd Po, until disease progression or continuous evaluation for 6 cycles.To evaluate the efficacy and safety of this two durgs. Results Two groups of disease control rate of DCR, there were significant differences （ apatinib than capecitabine, P〈0.05 ） . apatinib group and PFS capecitabine group were 3.6 months and 3.5 months, there was no statistically significant difference （ P〉0.05 ） . The leukopenia and thrombocytopenia in capecitabine group were higher than that in apatinib group, the hypertension and proteinuria of apatinib group were higher compared with capecitahine group, and they had statistical significance. Conclusion Apatinib and capecitabine in treatment of advanced gastric cancer with failed three lines and above drug treatment, curative effect of apatinib is better than that of capecitabine, there was significant difference. The long- term survival time does not exist significant difference, the adverse effect of different apatinib including hypertension, proteinuria, and capecitahine are mainly bone marrow suppression. But overall, the toxic and side effects are low and tolerable and it is worth popularizing in the clinic.
出处
《浙江临床医学》
2018年第1期50-52,共3页
Zhejiang Clinical Medical Journal
关键词
晚期胃癌
靶向治疗
阿帕替尼
卡培他滨
Stomach Neoplasms Targeted therapy Apatinib Capecitabine
